Published in J Cardiovasc Pharmacol Ther on September 01, 2004
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol (2008) 2.39
Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart (2006) 2.33
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol (2006) 1.70
Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. Am J Physiol Heart Circ Physiol (2010) 1.66
Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace (2007) 1.57
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol (2007) 1.38
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol (2011) 1.30
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol (2009) 1.04
New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol (2009) 1.02
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci (2008) 0.97
The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol (2006) 0.97
Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Heart Rhythm (2012) 0.96
Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol (2009) 0.90
Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol (2015) 0.90
Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther (2013) 0.89
Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br J Pharmacol (2008) 0.89
International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol (2008) 0.87
Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. Ann N Y Acad Sci (2010) 0.86
Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83
QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. J Anesth (2013) 0.83
Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injury. Am J Physiol Heart Circ Physiol (2009) 0.82
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants. J Mol Cell Cardiol (2014) 0.81
Anti-anginal and anti-ischemic effects of late sodium current inhibition. Cardiovasc Drugs Ther (2013) 0.75
Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation. Electrofisiol Arritm (2010) 0.75
Cholinergic Interneurons Amplify Corticostriatal Synaptic Responses in the Q175 Model of Huntington's Disease. Front Syst Neurosci (2016) 0.75
Update on ranolazine in the management of angina. Vasc Health Risk Manag (2014) 0.75
Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol (2016) 0.75
Therapeutic Strategies Targeting Inherited Cardiomyopathies. Curr Heart Fail Rep (2017) 0.75
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature (2004) 3.65
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol (2006) 2.56
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem (2002) 2.16
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol (2008) 2.09
Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol (2010) 2.04
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest (2006) 1.94
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Quantum plasmon resonances controlled by molecular tunnel junctions. Science (2014) 1.89
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem (2003) 1.88
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol (2007) 1.77
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol (2004) 1.77
Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res (2003) 1.70
Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res (2011) 1.69
Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol (2011) 1.69
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (2011) 1.68
Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res (2002) 1.64
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging (2009) 1.63
Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol (2012) 1.57
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 1.52
CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc Drugs Ther (2007) 1.52
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Deranged sodium to sudden death. J Physiol (2015) 1.51
Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther (2008) 1.50
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging (2009) 1.48
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol (2003) 1.46
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol (2007) 1.42
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol (2008) 1.35
Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol (2007) 1.32
Comparison of K+ currents in cardiac Purkinje cells isolated from rabbit and dog. J Mol Cell Cardiol (2006) 1.30
TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer (2011) 1.30
Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol (2006) 1.30
Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther (2005) 1.28
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther (2005) 1.27
Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm (2008) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol (2010) 1.26
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet (2006) 1.24
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther (2012) 1.23
Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm (2009) 1.23
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One (2012) 1.23